ANAB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AN

Mkt Cap

$1.39B

Volume

303.29K

Next Earnings

November 3rd

Loading chart

AN

ANABAnaptysBio, Inc. Common Stock

ANAB

Pay with—

Available Balance0.00

AN

Mkt Cap

$1.39B

Volume

303.29K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesAnaptysBio (ANAB) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.46 loss, with a 76% earnings surprise. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Medical - Biomedical and Genetics industry ranks in the bottom 32% of sectors. Nurix Therapeutics (NRIX) is expected to report results with a projected loss of $0.56 per share but with significant revenue growth of 1665.8% year-over-year.Zacks Investment Research · Sep 21, 2026

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach ClaimA Delaware Chancery Court dismissed Tesaro's (GSK subsidiary) anticipatory breach of contract claim against AnaptysBio, rejecting requests for royalty reductions on Jemperli. The ruling affirms Anaptys has not repudiated the collaboration agreement and validates the company's efforts to protect its contractual rights. A trial is scheduled for July 14-17, 2026, where Anaptys will pursue claims that Tesaro/GSK materially breached the agreement and seek potential reversion of Jemperli.GlobeNewswire Inc. · Apr 24, 2026

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiaryAnaptysBio filed a motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court regarding their Collaboration Agreement over royalties from Jemperli (dostarlimab). Anaptys claims it sought good faith discussions to resolve alleged breaches by Tesaro and GSK, but Tesaro initiated a lawsuit without notice. The court is expected to hear arguments by early March, with trial scheduled for July 14-17, 2026.GlobeNewswire Inc. · Jan 8, 2026

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli RoyaltiesGSK's subsidiary Tesaro has filed a lawsuit against AnaptysBio in Delaware Chancery Court, alleging breach of a license agreement for the cancer drug Jemperli, and seeking to protect its royalty rights.Benzinga · Nov 21, 2025

Anaptys Initiates Litigation Against Tesaro, a GSK SubsidiaryAnaptysBio filed a legal complaint in Delaware Chancery Court against Tesaro and GSK, alleging material breaches of their Collaboration Agreement, specifically related to PD-1 antagonist research and commercial efforts for the drug Jemperli.GlobeNewswire Inc. · Nov 21, 2025

12 Health Care Stocks Moving In Monday's After-Market SessionMultiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.Benzinga · Sep 29, 2025

Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsightThe psoriasis pipeline has several drugs in mid- and late-stage development, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to positively impact the market. The treatment landscape is expanding with new therapies from various companies.GlobeNewswire Inc. · Apr 14, 2025

Why AnaptysBio Was Such a Healthy Stock This WeekAnaptysBio, a clinical-stage biotech company, has seen its stock price rise recently. A positive research note from Guggenheim analyst Yatin Suneja, who reiterated a buy rating and $75 price target, cites an upcoming phase 2 clinical trial readout for the company's atopic dermatitis drug and Sanofi's financial involvement as reasons for optimism.The Motley Fool · Aug 23, 2024

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct OfferingAnaptysBio, a clinical-stage biotechnology company, announced the pricing of a $100 million underwritten offering of its common stock. The offering was led by existing investor EcoR1 Capital and included participation from new and existing investors, including Sanofi.GlobeNewswire Inc. · Aug 14, 2024

Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.Zacks Investment Research · Jun 24, 2024

to start trading

AN

ANABAnaptysBio, Inc. Common Stock

ANAB

Pay with—

Available Balance0.00

Your PositionYou don't own any ANAB yet.

Related Tickers

Earnings